Advanced search    

Search: authors:"Francesco Crea"

11 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation

, Francesco Crea, Martin D. Bootman. Data curation: Lorenzo Fornaro, Caterina Vivaldi, Dong Lin, Hui Xue, Alfredo Falcone, Yuzhuo Wang, Francesco Crea, Martin D. Bootman. 9 / 12 Formal analysis: Lorenzo ... Fornaro, Caterina Vivaldi, Dong Lin, Hui Xue, Alfredo Falcone, Yuzhuo Wang, Francesco Crea, Martin D. Bootman. Investigation: Lorenzo Fornaro, Caterina Vivaldi, Dong Lin, Hui Xue, Alfredo Falcone, Yuzhuo

Polycomb-mediated silencing in neuroendocrine prostate cancer

Background Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PCa) for which the median survival remains less than a year. Current treatments are only palliative in nature, and the lack of suitable pre-clinical models has hampered previous efforts to develop novel therapeutic strategies. Addressing this need, we have recently established the...

The non-coding transcriptome as a dynamic regulator of cancer metastasis

Since the discovery of microRNAs, non-coding RNAs (NC-RNAs) have increasingly attracted the attention of cancer investigators. Two classes of NC-RNAs are emerging as putative metastasis-related genes: long non-coding RNAs (lncRNAs) and small nucleolar RNAs (snoRNAs). LncRNAs orchestrate metastatic progression through several mechanisms, including the interaction with epigenetic...

Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer

Background While localized prostate cancer (PCa) can be effectively cured, metastatic disease inevitably progresses to a lethal state called castration-resistant prostate cancer (CRPC). Emerging evidence suggests that aberrant epigenetic repression by the polycomb group (PcG) complexes fuels PCa progression, providing novel therapeutic opportunities. Results In the search for...

Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer

Background The enhancer of zeste-homolog 2 (EZH2) is involved in cancer development through gene silencing by trimethylation of lysine 27 of histone 3 (H3K27me3). The C/C genotype for the EZH2 rs3757441 single-nucleotide polymorphism (SNP) is linked with poor prognosis in metastatic colorectal cancer (CRC), but molecular and pathological characterization of this SNP is lacking...

The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo

Background Long non-coding RNAs (lncRNAs) can orchestrate oncogenic or tumor-suppressive functions in cancer biology. Accordingly, PCGEM1 and PRNCR1 were implicated in progression of prostate cancer (PCa) as transcriptional co-regulators of the androgen receptor (AR). However, these findings were recently refuted asserting that neither gene physically binds to the AR. Despite...

The emerging role of histone lysine demethylases in prostate cancer

Early prostate cancer (PCa) is generally treatable and associated with good prognosis. After a variable time, PCa evolves into a highly metastatic and treatment-refractory disease: castration-resistant PCa (CRPC). Currently, few prognostic factors are available to predict the emergence of CRPC, and no curative option is available. Epigenetic gene regulation has been shown to...

Clinical significance of Polycomb gene expression in brain tumors

Polycomb group (PcG) proteins are crucial for neural cancer stem cell (NCSC) self-renewal. However, the relative expression levels of PcG genes in different subtypes of brain tumors, their prognostic role and their effects on cellular pathways have not been investigated. For this purpose, we queried the Oncomine database and found that 4 PcG genes (EZH2, RBBP7, SUZ12, YY1) are...

Dioxouranium(VI)-Carboxylate Complexes. Interaction of UO 2 2+ with 1,2,3,4,5,6-Benzenehexacarboxylate (Mellitate) in 0≤I(NaClaq)≤1.0 mol⋅L−1

J Solution Chem of UO2+ with 1,2,3,4,5,6-Benzenehexacarboxylate 2 Francesco Crea Alessandro De Robertis Concetta De Stefano Silvio Sammartano Erratum to: J Solution Chem (Mellitate) in 0 ≤ I

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer

Background Polycomb repressive complex 2 (PRC2) mediates gene silencing through histone H3K27 methylation. PRC2 components are over-expressed in metastatic prostate cancer (PC), and are required for cancer stem cell (CSC) self-renewal. 3-Dezaneplanocin-A (DZNeP) is an inhibitor of PRC2 with broad anticancer activity. Method we investigated the effects of DZNeP on cell...

Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients

Ilaria Pastina Elisa Giovannetti 0 Aldo Chioni Tristan M Sissung Francesco Crea 0 Cinzia Orlandini Douglas K Price Claudia Cianci William D Figg Sergio Ricci Romano Danesi 0 0 Division of